HeartFlow Surges Ahead with Record-Breaking Q1 2026 Performance
HeartFlow, a leading healthcare technology company, has reported an impressive first quarter (Q1) performance in 2026, with revenue reaching $52.6 million, representing a 41% year-over-year growth.
The company's AI-powered platform, combined with its deeply embedded commercial footprint and the world's largest database of annotated CCTA images (over 200 million), has created an advantage that widens with every quarter. This strong momentum is expected to continue, as HeartFlow has now helped physicians manage care for more than 650,000 patients worldwide.
In a conference call on May 14, 2026, John Farquhar, HeartFlow's President and Chief Executive Officer, highlighted the key factors that drove the company's Q1 performance. Firstly, FFRCT utilization remains strong across the installed base, with a record class of new accounts added in 2025 performing well and ramping on schedule. Secondly, the Plaque launch is outperforming expectations, with activation of new Plaque accounts ahead of schedule and strong early utilization trends.
The broader CCTA market continued to expand, supported by guidelines and strong reimbursement. HeartFlow's unique product differentiation has resulted in a large and growing cohort of legacy FFRCT accounts delivering consistent and predictable volumes month-over-month. Additionally, the performance of new accounts added into the installed base in 2025 is ramping nicely in line with expectations.
The company's Plaque business is also accelerating ahead of expectations, with adoption driven by the recently published ACC/AHA scientific statement on Plaque, increasing payer coverage, and outstanding clinical and economic evidence. This has contributed to growing awareness and demand for HeartFlow's Plaque Analysis.
As a result of this strong performance, HeartFlow has raised its full-year outlook, expecting total revenue of $228 million-$232 million, representing 29%-32% year-over-year growth. The company is also increasing its Plaque-specific revenue outlook to $19 million-$21 million and raising its non-GAAP gross margin guidance to approximately 81%, driven by ongoing AI efficiencies, volume leverage, and a higher mix of high-margin Plaque revenue.
HeartFlow's President and CEO, John Farquhar, expressed confidence in the company's performance, stating that the strength of their Q1 results gives them "confidence to raise our full-year outlook." He also highlighted the significance of reaching a meaningful milestone this quarter, having now helped physicians manage care for more than 650,000 patients worldwide.
The company remains committed to its midterm non-GAAP gross margin target of 85% and is confident in its ability to deliver strong results moving forward. As HeartFlow continues to innovate and expand its commercial footprint, investors are likely to remain optimistic about the company's future prospects.
